# Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

> **NCT02121509** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 74 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Linagliptin
- **DRUG:** Linagliptin/Metformin ER FDC
- **DRUG:** Metformin ER

## Key facts

- **NCT ID:** NCT02121509
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2016-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02121509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02121509, "Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02121509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*